Artelo Biosciences (ARTL) Corporate presentation summary

Strategic focus and pipeline

• Advancing a platform of lipid signaling modulation drug candidates targeting pain, cancer, anxiety, depression, and other conditions.

• Lead programs include ART27.13 (dual cannabinoid receptor agonist), ART26.12 (FABP5 inhibitor), and ART12.11 (CBD:TMP cocrystal).

• Multiple value-driving milestones expected in the next 12–18 months, including Phase 2 and preclinical studies.

• Targeting billion-dollar markets such as cancer anorexia, CIPN, prostate and breast cancer, psoriasis, anxiety, and glaucoma.

• Robust patent estate with 38 issued and 51 pending patents, ensuring strong market exclusivity.

ART27.13 program highlights

• Designed for cancer-related anorexia and cachexia, conditions affecting up to 80% of advanced cancer patients with no FDA-approved treatments.

• Demonstrated dose-dependent weight gain and increased activity in clinical studies, with a favorable safety profile up to 1300 μg.

• Phase 2 CARES trial interim data showed an average 6% weight increase at highest dose versus 5% decrease with placebo.

• Most common adverse events were mild, including vomiting and dry mouth; no serious or fatal events related to treatment.

• Peripherally selective to avoid CNS side effects, leveraging established appetite pathways.

ART26.12 program highlights

• FABP5 inhibitor targeting chemotherapy-induced peripheral neuropathy (CIPN), a condition with no FDA-approved therapies affecting up to 40% of treated cancer patients.

• Preclinical studies showed significant reversal of neuropathic pain symptoms in animal models.

• Phase 1 study in healthy volunteers demonstrated excellent safety, predictable pharmacokinetics, and a wide therapeutic window.

• Potential for non-opioid, non-psychoactive pain and inflammation management.

• Worldwide exclusive license for multiple generations of FABP inhibitors from Stony Brook University.